Opicapone

Introduction Overview

Generic Name

opicapone

Brand Name

Ongentys

Dosage Form

oral capsules

Drug Class

Dopaminergic antiparkinsonism agents

Pharmacokinetics

Absorption:
Opicapone is administered orally and is rapidly absorbed from the gastrointestinal tract. The drug is typically taken at bedtime on an empty stomach, with no food for at least one hour before or after dosing, to optimize bioavailability and interaction with levodopa absorption. Pharmacokinetic studies demonstrate that its plasma concentrations peak several hours post-dose. Its absorption is not significantly affected by gastric pH but co-administration with levodopa/carbidopa benefits from temporal separation to reduce interference in levodopa absorption phase, allowing increased levodopa bioavailability.

Distribution:
Opicapone exhibits a moderate volume of distribution, indicating its capacity to distribute into various body tissues. Upon absorption, it binds extensively to plasma proteins, predominantly albumin, which influences its pharmacodynamics and half-life. CNS penetration is essential given its role in Parkinson's disease management, where it targets central COMT enzymes to prolong levodopa's effects. Animal studies and clinical data suggest sufficient CNS bioavailability to exert therapeutic action without causing significant blood-brain barrier toxicity.

Metabolism:
The primary metabolic pathway of opicapone involves conjugation reactions, predominantly sulfation and glucuronidation in the liver. It is a peripheral, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). Extensive hepatic metabolism by phase II enzymes reduces the active substance, producing inactive metabolites that are subsequently eliminated. Unlike some COMT inhibitors, opicapone does not undergo significant cytochrome P450 metabolism, lowering the risk of pharmacokinetic drug interactions via this pathway.

Elimination:
Opicapone's elimination predominantly occurs via feces, with approximately two-thirds of the administered dose excreted this way, and the remainder primarily eliminated renally. The elimination half-life of opicapone supports once-daily dosing. The pharmacokinetics are not substantially altered in mild to moderate renal impairment, but caution is advised in severe renal or hepatic dysfunction. Because of its metabolism and elimination profile, opicapone accumulates minimally and does not require dosage adjustment in most patient populations. Clinical monitoring is important to observe efficacy and adverse effects in long-term therapy.

Dosage Forms

Available Dosage Forms:
Ongentys is available as oral capsules formulated specifically for once-daily administration.

Dosages for Adults and Adolescents:
The recommended dose for adults with Parkinson's disease experiencing 'off' episodes is 50 mg orally once daily at bedtime. This dosing regimen optimizes the drug's effect on COMT inhibition, enhances central levodopa bioavailability throughout the day, and minimizes adverse events.

Specific Patient Populations:
Ongentys has not been established as safe or effective in pediatric populations; therefore, it is not recommended for children. Special caution is required in patients with hepatic and renal impairment, where clinical monitoring and careful dose titration may be necessary. Elderly patients also require close observation for side effects such as somnolence and orthostatic hypotension.

Specific Dose Formulations:
- Oral capsule: 50 mg
No other oral strengths or formulations such as liquids or chewables are currently marketed for opicapone.

Mechanism Of Action

Opicapone is a highly selective and potent inhibitor of the enzyme catechol-O-methyltransferase (COMT), which plays a critical role in the metabolic degradation of catecholamines including dopamine, epinephrine, and norepinephrine. In Parkinson's disease, central dopaminergic neurons are depleted, and oral levodopa therapy is converted to dopamine in the brain, yet peripheral metabolism by COMT limits levodopa's bioavailability. Opicapone inhibits peripheral COMT irreversibly, thereby prolonging the half-life of levodopa and increasing its plasma levels.

At the molecular level, opicapone binds to the COMT enzyme at its active site, preventing the methylation and subsequent inactivation of levodopa. This results in a sustained increase in levodopa availability which allows for enhanced and prolonged dopaminergic stimulation of the striatal neurons, thereby improving motor function and reducing 'off' episodes characterized by rigidity, tremor, and bradykinesia.

Cellular pathways affected by opicapone include dopaminergic neurotransmission circuits within the basal ganglia, which are crucial for motor control. By maintaining higher levels of dopamine in the synaptic cleft, opicapone augments postsynaptic dopaminergic receptor activation. This pharmacodynamic effect translates clinically into improved 'on' time without dyskinesia and smoother motor control in patients receiving levodopa/carbidopa therapy.

Compared to other COMT inhibitors like entacapone and tolcapone, opicapone demonstrates longer-lasting COMT inhibition, allowing for once-daily dosing with reduced pill burden. Its peripheral selectivity reduces central nervous system-related adverse effects, and its minimal hepatic cytochrome P450 involvement diminishes drug interaction risks. Clinical trials establish opicapone as superior in reducing 'off' time and improving quality of life parameters in Parkinson's disease patients experiencing motor fluctuations.

Pharmacological Actions

Selective and reversible inhibition of peripheral catechol-O-methyltransferase (COMT) enzyme.
Prolongation of levodopa half-life and increased plasma levodopa concentrations.
Enhancement of central dopaminergic neurotransmission by increasing dopamine bioavailability.
Reduction of 'off' episodes and motor fluctuations in Parkinson’s disease patients on levodopa/carbidopa therapy.
Peripheral COMT inhibition minimizes central nervous system adverse effects.
Once-daily dosing supports better patient compliance.
Does not inhibit monoamine oxidase enzymes, reducing risk of serotonergic toxicity.
Lack of significant cytochrome P450 metabolism reduces pharmacokinetic drug-drug interactions.
Improves motor control by sustaining synaptic dopamine levels in striatum.
Contributes to increased 'on' time without dyskinesia development.
Peripheral metabolic enzyme targeting allows combination with levodopa/carbidopa for enhanced efficacy.

Therapeutic Or Clinical Uses

Adjunctive treatment with levodopa/carbidopa to manage 'off' episodes in Parkinson's disease.
Improvement of motor fluctuations such as sudden immobility and stiffness in Parkinson’s patients.
Reduction in duration and frequency of 'off' episodes during levodopa therapy.
Enhancement of daily motor function and patient quality of life.
Management of end-of-dose wearing off phenomena common in advanced Parkinson’s disease.
Use in patients who have inadequate motor response to levodopa alone.
Treatment option for patients experiencing fluctuating dopamine levels.
Preferred once-daily oral therapy improving treatment adherence.
May be used in combination with other dopaminergic agents to optimize motor symptom control.
Potential to reduce required daily levodopa dose by increasing its efficacy.
Useful in patients intolerant to other COMT inhibitors due to favorable side effect profile.

Side Or Adverse Effects

Light-headedness and dizziness, potentially causing falls or accidents.
Uncontrolled muscle movements including dyskinesia and facial tics.
Constipation as a common gastrointestinal adverse event.
Weight loss observed in some patients during therapy.
Elevations in certain blood laboratory tests indicating metabolic changes.
Hallucinations, confusion, agitation, and other neuropsychiatric manifestations.
Allergic reactions including hives, facial swelling, and difficulty breathing.
Exacerbation or worsening of Parkinsonian symptoms such as tremors and stiffness.
Sudden onset of sleep episodes or excessive daytime sleepiness potentially impairing safety.
Impulsive or compulsive behaviors such as pathological gambling or binge-eating.
Withdrawal symptoms upon abrupt discontinuation including muscle rigidity, fever, and autonomic instability.
Orthostatic hypotension with associated risk of syncope.
Possible hepatic side effects necessitating liver function monitoring.
Rare reports of psychosis or hallucinations requiring dose adjustment.
Low risk for serious cardiovascular adverse events.

Precautions

Do not use in patients with known allergy to opicapone or components of Ongentys capsules.
Avoid use in individuals with tumors secreting catecholamines such as pheochromocytoma or paraganglioma.
Monitor patients for signs of excessive sedation or sudden sleep onset during activities.
Caution in individuals with pre-existing sleep disorders, including narcolepsy.
Use with care in patients exhibiting impulse control disorders or psychiatric illness.
Adjust concomitant Parkinson’s medications carefully when initiating or discontinuing Ongentys.
Periodic blood pressure monitoring is recommended due to risk of orthostatic hypotension.
Assess liver and kidney function before and during treatment to detect metabolic impairments.
Patients should avoid driving or hazardous tasks until individual response to therapy is assessed.
Medication adherence to dosing schedule is critical; take on empty stomach to improve absorption.
Close monitoring for worsening motor symptoms or onset of dyskinesia is necessary.
Warn about potential drug interactions with other catecholaminergic or CNS depressant agents.
Pregnancy safety has not been established; use only if benefits outweigh risks.
Breastfeeding mothers should consult healthcare providers before use.
Avoid abrupt discontinuation to minimize risk of withdrawal and neuroleptic malignant syndrome-like symptoms.

Warnings

Contraindicated in patients who have used monoamine oxidase (MAO) inhibitors within 14 days including isocarboxazid, phenelzine, linezolid, tranylcypromine, and methylene blue injection.
Do not use if patient has pheochromocytoma or paraganglioma due to risk of hypertensive crisis.
Discontinue immediately if signs of serious allergic reactions occur, such as angioedema or anaphylaxis.
Risk of severe drowsiness and sudden sleep onset, advising caution with activities requiring alertness.
Potential exacerbation of impulse control disorders; monitor for compulsive behavior changes.
Risk of neuroleptic malignant syndrome-like reactions on sudden withdrawal.
May cause orthostatic hypotension with syncope risk, especially in elderly patients.
Use with caution in patients with psychiatric disorders; may induce hallucinations or psychosis.
Careful titration required when added to other dopaminergic therapies to avoid dopamine overdose.
Avoid concomitant use with other COMT inhibitors or drugs metabolized via COMT pathway.
Potential for increased liver enzyme levels may require periodic hepatic monitoring.
Not recommended in pediatric patients due to unknown safety and efficacy profile.
Patients should be made aware of drug interactions that could potentiate sedative effects or cardiovascular risks.
Emergency medical attention is necessary in case of overdose or serious adverse effects.
Pregnancy and lactation safety not fully established; only use if clearly needed.

Contraindication

Hypersensitivity or allergy to opicapone or any component of the formulation.
Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs).
Presence of catecholamine-secreting tumors including pheochromocytoma or paraganglioma.
Known hypersensitivity reactions to other COMT inhibitors that may cross-react.
Severe hepatic impairment due to altered metabolism and increased risk of toxicity.
Use in pediatric populations owing to lack of established safety and efficacy data.
Patients with history of severe neuropsychiatric illness prone to hallucinations or psychosis.
Co-administration with medications strongly interacting via COMT enzyme leading to adverse effects.
Concurrent use with other COMT inhibitors (e.g., entacapone, tolcapone) due to additive effects.
Uncontrolled cardiovascular conditions that may be worsened by sympathomimetic effects.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, phenelzine, tranylcypromine, and linezolid leading to risk of hypertensive crisis.
Dopaminergic agents including levodopa, dopamine, and carbidopa requiring dose adjustments due to enhanced dopaminergic effects.
Sympathomimetic drugs such as dobutamine, epinephrine, norepinephrine, and isoproterenol where combined use may amplify cardiovascular effects.
CNS depressants including opioids, benzodiazepines, muscle relaxants, and antiepileptics may potentiate sedation and risk of respiratory depression.
Drugs affecting dopamine metabolism or receptor activity which may cause additive adverse reactions or altered efficacy.
Agents altering gastrointestinal motility or absorption potentially impacting opicapone bioavailability.
Pharmacokinetic interactions with drugs metabolized by COMT are minimal, but vigilance with polypharmacy is warranted.
Medications causing orthostatic hypotension may increase syncope risk in combination with Ongentys.
Herbal supplements and vitamins with dopaminergic properties might alter therapeutic outcomes or adverse effect profiles.
Drugs causing QT prolongation should be monitored when combined due to additive cardiac risks.
Antipsychotics that antagonize dopamine receptors may reduce the clinical efficacy of opicapone.
Caution when combining with other serotonergic agents due to theoretical risk of serotonin syndrome.
No significant cytochrome P450 interactions, enhancing safety with polypharmacy situations.
Concomitant use with levodopa dosing should be temporally adjusted to prevent absorption interference.
Avoid co-administration with other COMT inhibitors to prevent additive toxicity or excessive dopamine levels.

Preparations Of The Drug

Ongentys oral capsules containing 50 mg opicapone.
Capsules designed for once-daily administration at bedtime to optimize dopaminergic effects.
Packaged in blister packs or bottles ensuring protection from moisture and heat.
Available in prescription-only status for treatment of Parkinson’s disease motor fluctuations.
Formulated to favor peripheral COMT inhibition without significant blood-brain barrier penetration.
No currently marketed oral liquid, tablet, or alternative dosage forms.
Instructions to take on an empty stomach—no food 1 hour before or after dosing to ensure maximal bioavailability.
Storage conditions involve room temperature, protected from moisture and excessive heat.
Supplied with medication guide and patient instructions emphasizing dosing schedule adherence and side effect monitoring.
Manufactured under stringent quality control standards meeting regulatory requirements.
Compatible with concomitant levodopa/carbidopa therapy as a fixed adjunctive treatment.
Product labeling specifies contraindications, precautions, and drug interaction warnings.
Effective packaging designed to minimize dosing errors and ensure stability over shelf life.
Patient education materials provided to facilitate understanding of usage and potential adverse events.